Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
Rhea-AI Summary
Co-Diagnostics (NASDAQ: CODX) was invited to present its Co-Dx MTB test on the Co-Dx PCR platform at the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026.
The company will present at a roundtable with U.S. government agencies and private-sector stakeholders. According to the company, the platform aligns with recent WHO guidance on near-point-of-care molecular diagnostics and tongue-swab testing. The Co-Dx PCR platform remains under FDA and other regulatory review and is not yet available for sale.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CODX
On the day this news was published, CODX gained 2.82%, reflecting a moderate positive market reaction. Argus tracked a peak move of +13.2% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $157K to the company's valuation, bringing the market cap to $5.71M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers showed mixed moves, with some up and others down, while CODX traded near its 52-week low; scanner data flagged only two peers with opposing directions, supporting a stock-specific read on this TB-focused news.
Previous Partnership Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Saudi JV facility | Positive | -4.9% | JV CoMira secured Saudi industrial land for a diagnostics manufacturing facility. |
| Feb 05 | India device license | Positive | +0.0% | CoSara received CDSCO license to manufacture and sell the PCR Pro instrument. |
| Dec 18 | TB course invite | Positive | +5.3% | CoSara invited to an advanced TB diagnostics course with global health partners. |
| Nov 05 | CoSara SPAC review | Positive | +3.5% | Company engaged Maxim Group to explore a SPAC or similar listing for CoSara. |
Partnership-related headlines have produced mixed single-day reactions with a modest average move, indicating that collaborative or visibility events have not consistently driven strong price trends.
Over recent months, CODX has emphasized partnerships and strategic initiatives. Prior partnership-tagged events included joint venture progress in Saudi Arabia, an Indian CDSCO instrument license, a TB diagnostics course invite, and exploration of a SPAC route for CoSara. These moves aimed to expand manufacturing, regulatory footing, and strategic options. Today’s Stop TB Partnership Summit invitation continues the theme of leveraging collaborations and global forums to position its TB and PCR platform efforts.
Historical Comparison
Partnership-tagged CODX headlines over four prior events saw an average 24h move of 0.96%, with mixed reactions. The Stop TB summit invitation extends this ongoing collaboration and TB diagnostics theme.
Partnership news has traced a path from SPAC exploration for CoSara, to CoSara’s CDSCO instrument license, to TB-focused educational engagement in India, and CoMira’s Saudi manufacturing plans. The new Stop TB Partnership Summit appearance adds another global platform connection around TB and molecular diagnostics.
Market Pulse Summary
This announcement underscores CODX’s strategy of using global TB forums to spotlight its Co-Dx PCR platform and MTB test, which are aligned with recent WHO guidance but remain under regulatory review and not yet for sale. In context of 2025 revenue of $0.6M and a $46.9M net loss, investors may watch how such visibility translates into concrete regulatory milestones, commercialization steps, and updated partnership or JV arrangements.
Key Terms
molecular diagnostics medical
pcr platform medical
near-point-of-care medical
tongue swabs medical
fda regulatory
AI-generated analysis. Not financial advice.
MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership,
"We anticipate that the Co-Dx PCR platform, including the Co-Dx MTB test kit, has the potential to play a transformative role in where, how, and how often TB testing occurs, especially following recently-announced guidance from the World Health Organization related to near-point-of-care molecular diagnostics and easy-to-collect tongue swabs," said Dwight Egan, CEO of Co-Diagnostics. "We believe this is a timely opportunity to present the platform to representatives from so many other global stakeholders at this Summit dedicated to stopping TB."
The Stop TB Partnership Summit is being organized to catalyze and engage
The event is expected to highlight opportunities arising from the TB epidemic and identify methods to expand engagement in the global TB response. These efforts are intended to strengthen and broaden relationships between the public and private sectors and the Stop TB Partnership, supporting the development, evaluation and implementation of products aimed at helping end TB.
Last month, the Company shared that the World Health Organization ("WHO") recently released guidance related to near-point-of-care ("NPOC") molecular diagnostics and easy-to-collect tongue swabs for patients who cannot produce sputum samples, and that the Company's testing platform and Co-Dx MTB NPOC test* are already aligned with the WHO guidance.
*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential capabilities, performance, and impact of the Company's Co-Dx PCR platform and MTB test, the anticipated benefits of participation in the Stop TB Partnership Summit, and the potential role of the Company's technologies in addressing global tuberculosis testing needs. These forward-looking statements are based on current expectations, estimates, and projections, as well as management's beliefs and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described herein. Such risks and uncertainties include, but are not limited to, the Company's ability to obtain required regulatory approvals, the timing and success of product development and commercialization efforts, market acceptance of the Company's technologies, changes in global health priorities or funding, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise any such statements, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-invited-to-present-at-stop-tb-partnership-summit-in-washington-dc-302744309.html
SOURCE Co-Diagnostics